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Abstract 
Aim of the study was to evaluate gender-related differences in clinical status in patients with persistent 
non-valvular atrial fibrillation who were undergoing electrical cardioversion. 
Materials and Methods: We have examined 141 patients with persistent NVAF who were undergoing 
electrical cardioversion. Patients were examined: general clinical methods, assessment of clinical 
symptoms and background heart disease, BMI calculation, measurement of blood pressure, determination 
of laboratory parameters. All patients underwent ECG and transthoracic echocardiography. Patients were 
divided into two subgroups depending on gender.  
Results: Women with atrial fibrillation, which had sinus rhythm recovered by the electrical 
cardioversion, are older than men, they have a combination of several comorbid diseases and a higher 
risk of thromboembolic complications. Their clinical status is characterized by more symptomatic 
manifestations of arrhythmia, more severe HF and a significant renal impairment. Men are more prone to 
bad habits (smoking and alcohol abuse). 
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Introduction 
Atrial fibrillation (AF) is the most common clinically significant cardiac arrhythmia and a 
major risk factor for ischemic stroke and peripheral embolism. In 2010, the estimated numbers 
of men and women with AF worldwide were 20.9 million and 12.6 million [1]. AF in the 
general male population develops more often than in female, but after age 75 years, about 60% 
of the people with AF are women [2]. 
Recent studies demonstrated gender-related differences in clinical presentation, outcome, and 
management of patients with AF. This arrhythmia is independently associated with a two-fold 
increased risk of all-cause mortality in women and a 1.5-fold increase in men [3]. Female AF 
patients who have additional stroke risk factors (particularly older age) are also at greater risk 
than men of having a stroke [4]. Women with diagnosed AF can be more symptomatic than 
men and are typically older with more comorbidities [5, 6] but women appear less likely to 
receive specialist care and rhythm control therapy [7] while the outcomes of catheter ablation or 
AF surgery are comparable to those in men [8]. 
The analysis of the data of the AF - CARAF, FRACTAL, AFNET registers has shown that 
women with AF are more likely to seek for medical help, notice more significant influence of 
arrhythmias at the quality of life and they have the paroxysms of AF more often than men do [9]. 
Women are significantly undertreated, have a worse outcome, and importantly a reduced 
efficacy of the rhythm control strategy that appears to enhance cardiovascular morbidity and 
mortality. Furthermore, a decreased quality of life (QoL) in women vs. men regardless of 
treatment strategy (rhythm vs. rate control) has been recognized [10]. 
These observations highlight the need to offer effective diagnostic tools and therapeutic 
management equally to women and men. 
Aim of the study was of the study was to evaluate gender-related differences in clinical status 
in patients with persistent non-valvular atrial fibrillation (NVAF) who were undergoing 
electrical cardioversion (ECV). 
 
Materials and Methods 
We have examined 141 patients with persistent NVAF who were undergoing electrical 
cardioversion. The median of age (of lower-upper quartile) was 64 (57-70) years old. There 
were 95 (67%) men and 46 (33%) women in this study. 
38 (27%) patients have had the atrial fibrillation detected for the first time. Median follow-up 
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of arrhythmia was 2.0 years (0.83-4.0): 24 (17.0%) patients 
have had the atrial fibrillation diagnosed more than five years 
ago, 21 (15%) - up to 5 years ago, there were 48 patients 
(34%) who have had it detected less than 1 year and 48 
patients - up to 3 years ago. The median duration of the last 
episode of AF was 4 months (2.0-7.0). 
AF was associated with arterial hypertension (AH) - 81.6% of 
patients, obesity (63.1%) and ischemic heart disease (IHD) - 
26.2% of patients. Most often, patients had the combination of 
2 main diseases (AH and obesity) - 36.9%, 17.7% of patients 
had the combination of 3 diseases (IHD, AH and obesity), 4 
diseases (IHD, AH, obesity and chronic kidney disease) - 
10.6%. Only 8 patients (5.7%) had neither concomitant 
cardial pathology nor overweight. The study excluded patients 
with valvular heart disease, cardiomyopathy, constrictive 
pericarditis, heart failure in NYHA functional class IV, stage 
3 hypertension (systolic BP ≥180 or diastolic BP ≥110 
mmHg), decompensated hypo- or hyperthyroidism, patients 
who have undergone ablation. 
Patients were examined: general clinical methods (review of 
complaints, case history, life history), assessment of clinical 
symptoms and background heart disease, BMI calculation, 
measurement of blood pressure, determination of laboratory 
parameters. All patients underwent ECG and transthoracic 
echocardiography. 
For statistical analysis of the results we used biometric 
analysis methodology supported by STATISTICA 6.1 
software. Normal distribution was analysed by the mean value 
and mean error while non-normal distribution was analysed 
by the median and quartiles (Me [25–75]). Evaluation of the 
hypotheses was done using the Student’s t-criterion for 
comparison of mean variables and indicators for relative 
share. Differences were considered significant at p<0.05.  
 
Results and Discussion 
The ratio of men and women among patients with persistent 
non-valvular AF is 2:1. The mean age of males is 60.6 ± 9.7 
years old and women - 67.0 ± 8.2 years (р<0.0001). By the 
time of inclusion in the research females were significantly 
older: 63% of women were over 65 years old, while almost 
70% of males were under 65 years old (р<0.0001). Among all 
patients there were 79.5% of males under 65 years old and 
20.5%. of such women. 
By the moment of the AF episode, which was detected for the 
first time, females were significantly older (on the average 7 
years older - 64.0 ± 8.1 vs. 57.4 ± 10.4, р<0.0001).  
It is important that the duration of the anamnesis of 
arrhythmia of examined males and females did not differ - 3.2 
± 3.3 years and 3.2 ± 3.6 years. It should be noted that the 
third part of men (32.6%) was with the episode of arrhythmia 
detected for the first time, what is, although, not veraciously, 
but more than among women (19.6%) (p = 0.1). Males had 
less median of duration of the last relapse of arrhythmia than 
females (5.1 ± 4.9 months vs. 6.8 ± 6.3, p = 0.1) (Table 1).  
 
Table 1: Demographic features of the patients with persistent AF according to gender, M±SD (%) 
 
 
Men, 
n=95 
Women, 
n=46 р 
Ratios 2 1  
Age 
Under 65 years old 
Over 65 years old 
60,6±9,7 
66 (69, 5%) 
29 (30, 5%) 
67,0±8,2 
17 (37%) 
29 (63%) 
р<0,0001 
р<0,0001 
р<0,0001 
Since the beginning of arrhythmia, years old 
Under 65 years old 
Over 65 years old 
57,4±10,3 
73 (76, 8%) 
22 (23, 2%) 
64±8,1 
26 (56, 5%) 
20 (43, 5%) 
р<0,0001 
р<0,05 
р<0,05 
Duration of anamnesis of arrhythmia, years 3,2±3,3 3,2±3,6 0,999 
AF diagnosed for the first time 21 (32, 6%) 9 (19, 6%) p<0,1 
Duration of the last relapse of AF, months 5,1±4,9 6,8±6,3 p<0,1 
ECV in anamnesis 
1time 
>1 time 
 
16 (16, 8%) 
12 (8, 43%) 
 
5 (10, 9%) 
4 (12, 6%) 
 
 
Atrial fibrillation was symptomatic (EHRA> 1) for all the 
women without exception, while 25% of males did not feel 
any symptoms of arrhythmia (р<0.00001). Subjective 
symptoms of arrhythmia of more than half of the females 
(58.7%) were ІІІ functional class according to EHRA 
symptom scale, what is more than among males (45.3%; p = 
0.1). (Figure 1). The most common symptoms of arrhythmia 
were feeling of intense heartbeat, heart failure, dyspnea and 
weakness. 
 
 
 
Fig 1: Symptom severity according to EHRA symptom scale in patients with persistent AF. 
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Among the risk factors for cardiovascular diseases, males 
often had harmful habits: smoking (41.1% vs. 6.5%; 
р<0.0001) and alcohol abuse (13% vs. 5%; р<0.01) 
The risk of thromboembolic complications (TEC) according 
to the CHA2DS2-VASc among females on average was 4±1.7 
points, and among males it was 2.2 ±1.6 points (р<0.0001). 
Males often had a low risk of TEC: 14, 7 % didn`t have any 
AF (0 points), 20% had 1 point, 32,6% (р<0,05) had 2 points. 
Females in contrast with males more often had TEC in 
anamnesis (24% vs. 16.8%; р<0.05). (Table 2). 
 
Table 2: Risk factors for cardiovascular diseases and thromboembolic complications for patients with persistent AF according to gender, abs. 
(%) 
 
 
Men, 
n=95 
Women, 
n=46 p 
Family history of AF 22 (23%) 8 (17,4%) р<0,5 
Smoking 39 (41,1%) 3 (6,5%) р<0,0001 
Alcohol abuse 13 (13,7%) 2 (4,3%) р<0,05 
CHA2DS2-VASc score 
0 points 
1 point 
2 points 
3 points 
≥4 points 
2.2±1.6 
14 (14.7%) 
19 (20%) 
31 (32.6%) 
11 (11.6%) 
20 (21.1%) 
4.0±1.7 
0 
4 (8.7%) 
4 (8.7%) 
10 (21.7%) 
28 (60.9%) 
р<0,0001 
р<0,0001 
р<0,05 
р<0,0001 
р<0,0001 
 
The most common diseases associated with arrhythmia were 
combinations of arterial hypertension and obesity: almost half 
of the examined females (44%) and the third part of the males 
(34%) had it (Figure 2). 
Despite the fact that both sexes have the same anamnesis of 
arrhythmia, AF of the majority of females (59%) has appeared 
for the first time on the background of prolonged arterial 
hypertension (about 10-15 years). 54% of males have had 
arterial hypertension and AF diagnosed at the same time 
(р<0.01). However, women with arterial hypertension 
controlled their pressure more carefully than men. 
Atrial fibrillation of females more often developed depending 
on several background conditions. 15% of women have had 
the combination of 5 chronic diseases (IHD, AH, obesity, 
heart failure (HF), chronic kidney disease (CKD) diagnosed, 
this index for men was 5.3% (р<0.05). 28.3% of females vs. 
11.6% of males (р<0.05) had the combination of 3 diseases 
(AH, obesity and CKD). 
Man had lower symptoms of HF: 20% of patients had the first 
functional class HF according to the NYHA classification, 
and in the group of females only 8,7% (р<0,05) had it. 
Arrhythmia recurrence arose on the background of HF in 37% 
of women, which is more than in the group of men (23.2%, 
р<0.05). 
Women were more likely to have moderate reduction in 
glomerular filtration rate (Stage IIIb) - 30.4% vs. 11.6% of 
men (р<0.05). The majority of males (59%) had a decrease of 
glomerular filtration rate of the second stage, the percentage 
of females was twice less (32%) (р<0.01). 
 
 
 
Fig 2: Cardiovascular diseases associated with persistent atrial fibrillation according to gender. 
 
Conclusion 
Women with atrial fibrillation, which had sinus rhythm 
recovered by the electrical cardioversion, are older than men, 
they have a combination of several comorbid diseases and a 
higher risk of thromboembolic complications. Their clinical 
status is characterized by more symptomatic manifestations of 
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arrhythmia, more severe HF and a significant renal 
impairment. Men are more prone to bad habits (smoking and 
alcohol abuse). 
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